FMP
LakeShore Biopharma Co., Ltd.
LSBPW
NASDAQ
LakeShore Biopharma Co., Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was formerly known as YS Biopharma Co., Ltd. and changed its name to LakeShore Biopharma Co., Ltd in May 2024. LakeShore Biopharma Co., Ltd was founded in 2002 and is based in Beijing, China.
0.0546 USD
0.0186 (34.07%)
LSBPW Financial Statements
Year
2024
2023
2022
2021
Total Revenue
573.42M
687.2M
502.95M
257.02M
Cost of Revenue
117.69M
153.36M
117.07M
59.66M
Gross Profit
455.73M
533.84M
385.88M
197.36M
Operating Expenses
901.56M
647.15M
549.18k
319.68M
Research and Development
302.8M
318.7M
211.22M
94.39M
Selling, General & Administrative Expenses
428.09M
333.32M
549.18k
208.33M
Selling & Marketing Expenses
280.45M
251.56M
165.72M
69.44M
General & Administrative Expenses
147.65M
81.76M
107.05M
138.89M
Other Expenses
170.67M
-199.45k
-2.41M
-22.36M
Operating Income
-445.83M
-139.38M
-549.18k
-125.85M
Total Other Income/Expenses Net
-9.36M
-4.96M
17.89M
-48.52M
Income Before Tax
-455.19M
-144.35M
-545.73k
-174.37M
Income Tax
-21.73M
1.13M
4.94M
17.45M
Net Income
-433.46M
-145.48M
-545.73k
-191.83M
Basic EPS
-4.05
-1.88
-0.02
-6.67
EPS Diluted
-4.05
-1.88
-0.02
-6.67
Basic Average Shares
106.92M
77.42M
29.5M
28.75M
Diluted Average Shares
106.92M
77.42M
29.5M
28.75M
EBITDA
-368.66M
-76.8M
-67.2M
-116.78M
Retained Earning Schedule
Year
2024
2023
2022
Retained Earnings (Previous Year)
-1.87B
-19.32M
-3.64k
Net Income
-433.46M
-145.48M
-545.73k
Stock Repurchases
0
0
0
Dividend Paid
0
0
0
Retained Earnings
-2.31B
-1.87B
-19.32M
Other Distributions
-433.46M
-1.85B
-19.31M
PPE Schedule
Year
2024
2023
2022
Gross PPE
480.62M
582.89M
565M
Annual Depreciation
42.19M
36.69M
31.15M
Capital Expenditure
-44.25M
-57.05M
-298.93M
Net PPE
482.69M
603.25M
832.78M
Intangible and Goodwill Schedule
Year
2024
2023
2022
Acquisitions and Adjustments
0
0
0
Goodwill (Previous Year)
0
0
0
Goodwill
0
0
0
All figures are in CNY.
